HCV

0
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
2 programs
HCV, HBV, HIV testsN/A1 trial
HCV, HBV, HIV testsN/A
Active Trials
NCT04286347Terminated363Est. Oct 2021
Alliance Pharmaceuticals
1 program
Community-based Simplified HCV Testing and Treatment AlgorithmN/A1 trial
Active Trials
NCT06604182Not Yet Recruiting1,454Est. Jul 2026
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium N/A1 trial
Active Trials
NCT02452814Completed8Est. May 2017
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
ProphylaxisN/A1 trial
Active Trials
NCT05653232RecruitingEst. Mar 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Alliance PharmaceuticalsCommunity-based Simplified HCV Testing and Treatment Algorithm
Allergy TherapeuticsProphylaxis
Gilead SciencesHCV, HBV, HIV tests
RocheLong Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium

Clinical Trials (4)

Total enrollment: 1,825 patients across 4 trials

NCT06604182Alliance PharmaceuticalsCommunity-based Simplified HCV Testing and Treatment Algorithm

Innovate, Involve, Inspire

Start: Jan 2025Est. completion: Jul 20261,454 patients
N/ANot Yet Recruiting
NCT05653232Allergy TherapeuticsProphylaxis

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

Start: Apr 2023Est. completion: Mar 2027
N/ARecruiting
NCT04286347Gilead SciencesHCV, HBV, HIV tests

HCV, HBV, HIV Testing During Consultation With Anesthesiologist

Start: Aug 2021Est. completion: Oct 2021363 patients
N/ATerminated
NCT02452814RocheLong Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Start: May 2014Est. completion: May 20178 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,825 patients
4 companies competing in this space